Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3582-3586

  Chinsangaram, Jarasvech ^a   Honeychurch, Kady M ^a   Tyavanagimatt, Shanthakumar R ^a   Bolken, Tové C ^a   Jordan, Robert ^a,d   Jones, Kevin F ^a   Marbury, Thomas ^b   Lichtenstein, Israel ^c   Pickens, Margaret ^c   Corrado, Michael ^c   Landis, Patrick ^a   Clarke, Jean M ^a   Frimm, Annie M ^a   Hruby, Dennis E ^a  

^a SIGA Technologies Incorporated   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c SYNEOS HEALTH   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TECOVIRIMAT;

ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART REPOLARIZATION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORTHOPOXVIRUS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THERMOSTABILITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BENZAMIDES; CAPSULES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; ORTHOPOXVIRUS; YOUNG ADULT;

EID: 84862548012     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06090-11     Document Type: Article

References (13)

1. Bailey TR, et al. 2007. N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: identification of novel orthopoxvirus egress inhibitors. J. Med. Chem. 50:1442-1444.
2. Baker RO, Bray M, Huggins JW. 2003. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 57:13-23.
3. Henderson DA. 1999. The looming threat of bioterrorism. Science 283:1279-1282.
4. Henderson DA, et al. 1999. Smallpox as a biological weapon: medical and public health management. JAMA 281:2127-2137.
5. Institute of Medicine of the National Academies. 1999. Assessment of future scientific needs for live variola virus. National Academy Press, Washington, DC.
6. Jordan R, et al. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52:1721-1727.
7. Jordan R, et al. 2010. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 54:2560-2566.
8. LeDuc JW, Damon I, Relman DA, Huggins J, Jahrling PB. 2002. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis. 8:743-745.
9. National Institute of Allergy and Infectious Diseases. 2002. NIAID biodefense research agenda for CDC category A agents. National Institute of Allergy and Infectious Diseases, Bethesda, MD.
10. Quenelle DC, et al. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
11. Sbrana E, et al. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
12. Whitley RJ. 2003. Smallpox: a potential agent of bioterrorism. Antiviral Res. 57:7-12.
13. Yang G, et al. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.